Viral Hepatitis: Recent Advances in Diagnosis and Treatment, ESCMID Postgraduate Education Course

28 February - 1 March 2014, Istanbul, Turkey

  • ESCMID Study Group for Viral Hepatitis (ESGVH)
  • Infectious Diseases and Clinical Microbiology Specialty Society of Turkey (EKMUD)
  • Turkish Viral Hepatitis Society (VHSD)
Course Coordinator
  • Hakan Leblebicioglu, Samsun, Turkey
Course Objectives
  • Increase knowledge about viral hepatitis
  • Review the epidemiology, prevention and outcome of viral hepatitis
  • Enhance attendees' understanding of diagnosis of hepatitis
  • Increase knowledge about the treatment of viral hepatitis and follow-up
  • Demonstrate all the steps of diagnosis and treatment of chronic viral hepatitis through case discussions
Course Venue

DoubleTree by Hilton Istanbul Old Town
Ordu Cad. No: 31
34130 Beyazit
Istanbul, Turkey
Phone +90 212 453 58 00

Target Audience

50 – 100 infectious disease and clinical microbiology specialists and trainees, gastroenterologists and clinicians taking care of patients with viral hepatitis.

Attendance Grants

ESCMID provides a number of attendance grants for ESCMID “young scientist members”. The grant covers the registration fee, but not accommodation or
travel costs. Please apply online on this website (follow the link on the right) before 17 January 2014. Applicants will be informed about their acceptance by 31 January 2014.

Please note that attendance grant application does not include registration for the course. Please register separately with the link supplied on the right.

CME Accreditation

The organisers of the course will apply for European CME accreditation through EACCME.

Course Coordinator

Prof Hakan Leblebicioglu
Department of Infectious Diseases &
Clinical Microbiology
Ondokuz Mayis University Medical School
Samsun, Turkey

Phone +90 533 566 31 38
Fax +90 362 457 60 14

Administrative Secretariat

Hakkı Pehlivan
Humanitas MICE
Cumhuriyet Caddesi No: 105 / 734373
Elmadag Istanbul, Turkey

Phone +90 212 247 29 49
Fax +90 212 247 42 57

Course Programme

Presentations are availabe in the ESCMID Online Lecture Library.

Friday, 28 February 2014

09:00 Opening session

How to deal with guidelines for hepatitis C treatment
Chairs: F. Tabak & C. Hezode

09:15 Boceprevir and Telaprevir based triple therapy: guide to guidelines.
           U. S. Akarca

09:45 Management of patients with non 1 genotypes. A. Mangia
10:15 Management of acute HCV infection. A. Hoepelman
10:45 Coffee break

Challenges from a new era in hepatitis C treatment
Chairs: H. Vahaboglu & D. Salmon

11:00 Management of side effects of Telaprevir and Boceprevir. Z. Kocak Tufan
11:30 Pharmacogenomics and drugdrug interaction in the treatment of HCV                    chronic hepatitis. G. Di Perri
12:00 Hepatitis C treatment in developing countries: economic perspectives.
           R. Ozaras
12:30 Lunch

Future HCV treatment
Chairs: S. Kaymakoglu & B. Kilani

13:30 Anti HCV treatment: what’s coming in the next years. J. E. Arends
14:00 Pre-treatment and on-treatment predictors for decisions of anti HCV                         therapy. W. Irving

Round table: case studies (3 groups and rotate)*
14:30 Treatment of chronic hepatitis C in HIV-infected patients in the era of                        direct acting antivirals. D. Salmon
15:00 Coffee break
15:15 Difficult to treat patient 1: the multiexperienced patient, cirrhosis.
           C.  Hezode
15:45 Difficult to treat patient 2: cryoglobulinaemia, thrombocytopenia, renal                     disease, congenital anaemia. A. Hoepelman

* Round table case studies: case presentations with closed questions on 2 or 3 clinical turning points voted by the audience and discussed by the experts.

Saturday, 1 March 2014

Hepatitis B
Chairs: C. Agalar & J. E. Arends

09:00 Hepatitis B in the immunosuppressed patient. D. Salmon
09:30 Treatment of HBV in HIV infected patients. H. Kumbasar
10:00 Pregnancy and chronic hepatitis. H. Leblebicioglu
10:30 Coffee break

Diagnostic workshop (3 groups and rotate)
10:45 Molecular diagnosis of chronic hepatitis. V. Ghisetti
11:15 HBs Ag: new life for an old marker. V. Turhan
11:45 Non-invasive assessment of fibrosis. I. Koksal
12:15 Lunch

Hepatitis A and E
Chairs: H. Erdem & V. Ghisetti

13:30 Epidemiology of HEV. H. Dalton
14:00 Virology of HEV. W. Irving
14:30 HEV in immunocompromised hosts and pregnant women. B. Kilani
15:00 Coffee break

Other hepatitis issues
Chairs: C. Karaca & W. Irving

15:15 Indications and waiting list management in liver transplantation.
            Z. Karasu
15:45 Can we stop chronic hepatitis B treatment? R. Ozaras
16:15 What’s new in delta hepatitis? S. Hosoglu

16:45 Closing session

Faculty Members
  • C. Agalar, Istanbul, Turkey
  • U. S. Akarca, Izmir, Turkey
  • J. E. Arends, Utrecht, The Netherlands
  • H. Dalton, Truro, United Kingdom
  • G. Di Perri, Torino, Italy
  • H. Erdem, Istanbul, Turkey
  • V. Ghisetti, Torino, Italy
  • C. Hezode, Paris, France
  • A. Hoepelman, Utrecht, The Netherlands
  • S. Hosoglu, Diyarbakir, Turkey
  • W. Irving, Nottingham, United Kingdom
  • C. Karaca, Istanbul, Turkey
  • Z. Karasu, Izmir, Turkey
  • S. Kaymakoglu, Istanbul, Turkey
  • B. Kilani, Tunis, Tunisia
  • Z. Kocak Tufan, Ankara, Turkey
  • I. Koksal, Trabzon, Turkey
  • H. Kumbasar, Istanbul, Turkey
  • H. Leblebicioglu, Samsun, Turkey
  • A. Mangia, San Giovanni Rotondo, Italy
  • R. Ozaras, Istanbul, Turkey
  • D. Salmon, Paris, France
  • F. Tabak, Istanbul, Turkey
  • V. Turhan, Istanbul, Turkey
  • H. Vahaboglu, Istanbul, Turkey